Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

18.93USD
27 Jun 2017
Change (% chg)

-- (--)
Prev Close
$18.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
123,961
52-wk High
$25.95
52-wk Low
$6.31

ZYNE.OQ

Chart for ZYNE.OQ

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)

Overall

Beta: --
Market Cap(Mil.): $250.82
Shares Outstanding(Mil.): 13.25
Dividend: --
Yield (%): --

Financials

BRIEF-Zynerba Pharmaceuticals initiates ZYN001 phase 1 clinical program

* Zynerba Pharmaceuticals initiates ZYN001 phase 1 clinical program

26 Jun 2017

BRIEF-Zynerba Pharma achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome

* Zynerba Pharmaceuticals achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome Source text for Eikon: Further company coverage:

08 Jun 2017

BRIEF-Zynerba Pharmaceuticals reports Q1 loss per share $0.60

* Zynerba Pharmaceuticals reports first quarter 2017 financial results and operational highlights

09 May 2017

BRIEF-Zynerba Pharmaceuticals qtrly loss per share $0.71

* Zynerba - top-line results from fab-c exploratory phase 2 clinical trial in pediatric patients with fragile x syndrome expected in q3 of 2017

27 Mar 2017

BRIEF-Zynerba Pharmaceuticals completes enrollment for ZYN002 in two phase 2 clinical trials for epilepsy and osteoarthritis

* Zynerba Pharmaceuticals announces completion of enrollment for ZYN002 in two Phase 2 clinical trials for epilepsy and osteoarthritis Source text for Eikon: Further company coverage:

13 Mar 2017

BRIEF-Zynerba Pharmaceuticals says estimates that as of Dec. 31 cash and cash equivalents were about $31 mln

* Zynerba Pharmaceuticals Inc - estimates that as of December 31, 2016 cash and cash equivalents were approximately $31.0 million Source text - http://bit.ly/2jp373S Further company coverage:

19 Jan 2017

BRIEF-Zynerba Pharmaceuticals announces proposed public offering of common stock

* Zynerba Pharmaceuticals announces proposed public offering of common stock

19 Jan 2017

More From Around the Web

Earnings vs. Estimates